Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.34 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16346447 | 0.91 | FABP4 (0.34) | PSIP1CYP3A4FABP4CTNNB1WNT3A | |
| SCHEMBL15441396 | 0.89 | PSIP1 (0.46) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL17784417 | 0.86 | PSIP1 (0.44) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL17784419 | 0.86 | PSIP1 (0.44) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL16341376 | 0.85 | PSIP1 (0.42) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL16346137 | 0.83 | PSIP1 (0.41) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL16341261 | 0.83 | PSIP1 (0.43) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL17788067 | 0.83 | PSIP1 (0.41) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL16341239 | 0.83 | PSIP1 (0.41) | PSIP1CYP3A4FABP4NR1I2CTNNB1 | |
| SCHEMBL16389248 | 0.83 | PSIP1 (0.41) | PSIP1CYP3A4FABP4NR1I2CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016714-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2018-09-19 | — | — | EP | claimed |
| US-9994509-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2018-06-12 | — | — | US | claimed |
| US-20160152543-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016714-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2016-05-11 | — | — | EP | claimed |
| WO-2015001125-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-01-08 | — | — | WO | claimed |
| EP-3016714-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2018-09-19 | — | — | EP | disclosed |
| US-9994509-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2018-06-12 | — | — | US | disclosed |
| US-9994509-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2018-06-12 | — | — | US | disclosed |
| US-9994509-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2018-06-12 | — | — | US | disclosed |
| US-20160152543-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152543-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152543-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-06-02 | — | — | US | disclosed |
| EP-3016714-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001125-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001125-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152543-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | POLRMT, MAVS, EIF2AK2 | PSIP1 819/4885CYP3A4 2282/4885FABP4 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.